A study led by NYU Langone Health researchers reveals that patients suffering from long COVID exhibit significant alterations in the choroid plexus (ChP), a brain structure associated with Alzheimer’s disease (AD). The findings indicate that these patients have a 10% larger ChP and reduced blood flow, correlating with known blood markers of AD and cognitive decline.
The research highlights that the enlarged ChP may signal potential future cognitive impairment, as it aligns with increased levels of proteins linked to Alzheimer’s progression. This suggests that the long-term immune response following COVID-19 may cause structural changes in the ChP, which plays a critical role in regulating brain health and immune responses.
These results underscore the importance of monitoring neurological symptoms in long COVID patients, as the ChP abnormalities could serve as a predictive marker for AD risk. As the study authors emphasize, understanding the relationship between long COVID and cognitive decline could inform future therapeutic strategies aimed at mitigating long-term neurological effects.
Start your 7-day trial and see what the database can do →
